- Conditions
- Asthma
- Interventions
- Pictorial Asthma Action Plan, Written Asthma Action Plan
- Behavioral
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Anterior Cruciate Ligament Rupture
- Interventions
- Oxycodone, Placebo oral tablet
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 14 Years to 40 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Tucker, Georgia
- Conditions
- Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency
- Interventions
- Diiodothyropropionic acid (DITPA)
- Drug
- Lead sponsor
- Roy E. Weiss, M.D.
- Other
- Eligibility
- Up to 18 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
- Interventions
- Opevesostat, Dexamethasone, Fludrocortisone acetate, Hydrocortisone, Abiraterone acetate, Prednisone acetate, Enzalutamide
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 63
- States / cities
- Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more
- Conditions
- Health Behavior
- Interventions
- Two informational emails with plan information, Standard notice of eligibility determination
- Behavioral
- Lead sponsor
- Office of Evaluation Sciences
- Federal
- Eligibility
- 0 Years to 74 Years
- Enrollment
- 42,470 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, Supratentorial Glioblastoma, Supratentorial Gliosarcoma
- Interventions
- P140K-MGMT, O6-benzylguanine, Photon Based Radiotherapy, temozolomide, Filgrastim, carmustine
- Biological · Drug · Radiation
- Lead sponsor
- Leland Metheny
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Hypoglycemia
- Interventions
- dasiglucagon, placebo, GlucaGen HypoKit
- Drug
- Lead sponsor
- Zealand Pharma
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Escondido, California • New Haven, Connecticut • Indianapolis, Indiana
- Conditions
- Retinal Vein Occlusion
- Interventions
- Dexamethasone intravitreal implant, Monthly Ranibizumab
- Drug
- Lead sponsor
- Brian Burke, MPH
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 116
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more
- Conditions
- HIV
- Interventions
- PRO 140 (350 mg), PRO 140 (525 mg), PRO 140 (700 mg)
- Drug
- Lead sponsor
- CytoDyn, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 562 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 12
- States / cities
- La Mesa, California • Palm Springs, California • San Francisco, California + 9 more
- Conditions
- Exudative Age-Related Macular Degeneration
- Interventions
- LHA510 ophthalmic suspension, LHA510 vehicle, Ranibizumab ophthalmic solution
- Drug
- Lead sponsor
- Alcon, a Novartis Company
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Chronic Pain
- Interventions
- buprenorphine
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Obstructive Sleep Apnea
- Interventions
- Propofol sedation, Dexmedetomidine sedation
- Drug
- Lead sponsor
- Erin Kirkham
- Other
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Fibrodysplasia Ossificans Progressiva (FOP)
- Interventions
- Anti-IL1 Therapy
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 6 Years to 30 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
- Interventions
- Naltrexone, Ketamine, Placebo
- Drug · Other
- Lead sponsor
- Corewell Health East
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Royal Oak, Michigan
- Conditions
- Asthma
- Interventions
- Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 75
- States / cities
- Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
- Conditions
- Solid Tumors
- Interventions
- RO7444973, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- high dose chemotherapy then autologous hematopoietic cell transplant
- Procedure
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Central Nervous System Lymphoma, Intraocular Lymphoma
- Interventions
- Intraventricular Rituximab Plus MTX
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Osteosarcoma, Leukemia, Lymphoma
- Interventions
- glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin
- Drug
- Lead sponsor
- BTG International Inc.
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Ovarian Cancer
- Interventions
- filgrastim, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14
- Biological · Procedure · Radiation
- Lead sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 3
- States / cities
- Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania
- Conditions
- Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Interventions
- High-dose Methotrexate
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 7 Years to 22 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 8
- States / cities
- Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 5 more
- Conditions
- Breast Cancer
- Interventions
- etoposide, ifosfamide, topotecan hydrochloride, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Tampa, Florida